In8bio Inc. clinical trial pipeline

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

1. Notable: / 2 Drug Resistant Immunotherapy With Activated, Gene Modified…/ 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide · Recurrent or Newly Diagnosed Glioblastoma Nov 4, 2026 Primary and study completion pushed from Dec 2025 to Dec 2026 In8bio Inc.·Phase 1/2· NCT05664243

• Stopped: terminated, suspended or withdrawn
• Notable: the plan changed
• Minor: routine updates